View Clinical Trial (Medical Research Study)
Nebivolol and Endothelial Regulation of Fibrinolysis
| City: |
|
Boulder |
| State: |
|
Colorado |
| Zip Code: |
|
80309 |
| Conditions: |
|
Prehypertension - Hypertension |
| Purpose: |
|
The investigators hypothesize that nebivolol will improve endothelial t-PA release in adult
humans with elevated blood pressure to a greater extent than either metoprolol or placebo.
The investigators further hypothesize that the improvement in the capacity of the vascular
endothelium to release t-PA with nebivolol is mediated, in part, by the compound's
antioxidant properties.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Subjects will be men and women of all races and ethnic backgrounds aged 45-65 years.
- Subjects will be prehypertensive/hypertensive defined as resting systolic blood
pressure >125 mmHg and <160 mmHg and/or diastolic >80 mmHg and <100 mmHg.
- All of the women in the study will be postmenopausal and not receiving hormone
replacement therapy (HRT) currently or in the preceding 3-year period.
- Candidates will be sedentary as determined from the Stanford Physical Activity
Questionnaire (<35 kcal/wk) and will not have engaged in any program of regular
physical activity for at least 1 year prior to the study.
Exclusion Criteria:
- Candidates who smoke (currently or in the past 7 years), report more than low-risk
alcohol consumption as defined as no more than 14 standard drinks/wk and no more than
4 standard drinks/day for men and 7 standard drinks/wk and 3 standard drinks/day for
women (a standard drink is defined as 12 ounces of beer, 5 ounces of wine, 1½ ounces
of 80-proof distilled spirits).
- Potential candidates who are taking cardiovascular-acting (i.e. statins, blood
pressure medication and aspirin) medications will not be eligible.
- Fasting plasma glucose >126 mg/dL.
- Potential candidates with a resting heart rate of < 50 beats/minute will be excluded.
- Use of hormone replacement therapy.
- In hypertensive subjects, a seated systolic blood pressure >160 mmHg or a seated
diastolic blood pressure >100 mmHg will be excluded.
|
| NCT ID: |
|
NCT01595516 |
| Primary Contact: |
|
Principal Investigator
Christopher DeSouza, Ph.D.
University of Colorado at Boulder
Jared Greiner, M.S.
Phone: 303-735-4955
Email: jared.greiner@colorado.edu
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Boulder, Colorado 80309
United States
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 25, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|